Estimating the potential health economic value of introducing universal opt-out testing for HIV in emergency departments in Italy
Italy faces challenges with late HIV diagnoses, which leads to worse health outcomes and higher healthcare costs. In Italy, the proportion of late diagnoses (i.e., a CD4 count <350 cells/mm3) has increased to 60% in 2020—10% higher than the European average (1). With an estimated 13,000–15,000 undiagnosed HIV cases in Italy, innovative testing strategies are urgently needed Read More >
When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal
In 2019, the previous UK government set the ambitious target of eliminating HIV transmission within the UK by 2030. While great progress has been made in HIV prevention and treatment in the UK, with England reaching the UNAIDS 95-95-95 target in 20231, past evidence suggested that the goal of ‘elimination’ by 2030 is unlikely to Read More >
Could universal opt-out HIV testing in Italian emergency departments be a cost-effective way of increasing HIV diagnosis rates in Italy?
In Italy, 60% of new HIV diagnoses are in people who already have advanced disease (i.e., a CD4 count <350 cells/mm3) (1). This highlights an urgent need for alternative screening strategies if Italy is to make progress towards achieving the UNAIDS target of diagnosing at least 95% of people living with HIV (2). Read More >
How can economic models inform decision-making about screening programmes?
Dr Elisabeth Adams, Managing Director and Founder of Aquarius Population Health, spoke at a continuing medical education webinar for health professionals hosted on September 23,2020 by the Consortium for Infectious Disease Control (CIDC). With increasing demands on time and resources, decision-makers in healthcare need information about how to create a safe, effective and cost-effective Read More >
Using an mRNA versus DNA test in the English cervical screening programme can save £15m annually and reduce unnecessary testing
The results of our economic evaluation comparing the use of mRNA and DNA assays in screening for cervical cancer in England were published in BMJ Open and are now available online. Results show large cost savings from avoiding unnecessary testing and follow-up, which can benefit women and healthcare services. Read More >